Payment overview · 2025
General Payments
$205.39
12 reported records · 4 companies
Healthcare provider profile · identity verified
Tonya Knoll, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HAYS, KS · NPI 1750357547
Verified facts
What the public records show
CMS Open Payments records show Tonya Knoll, D.O. received $205.39 in general payments during 2025 across 12 reported records.
Amgen Inc. accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.63 | 52.9% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.32 | 27.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.31 | 10.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.13 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.39 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.53 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.53 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 174 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 136 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 95 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 90 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 16 |
| Lisinopril | Lisinopril | 83 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 20 |
| Losartan Potassium | Losartan Potassium | 71 | 15 |
| Furosemide | Furosemide | 67 | 18 |
| Metformin Hcl | Metformin Hcl | 66 | 16 |
| Sertraline Hcl | Sertraline Hcl | 66 | suppressed |
| Simvastatin | Simvastatin | 64 | 14 |
| Omeprazole | Omeprazole | 63 | 14 |
| Alprazolam | Alprazolam | 59 | 11 |
| Gabapentin | Gabapentin | 59 | 11 |
| Potassium Chloride | Potassium Chloride | 56 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 51 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Meloxicam | Meloxicam | 46 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 42 | 42 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Eliquis | Apixaban | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 14 |
| Ozempic | Semaglutide | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 24 |
| Famotidine | Famotidine | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 14 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Temazepam | Temazepam | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.39 · 12 records | Amgen Inc. | Cologuard Collection Kit, EVENITY, MOUNJARO, OTEZLA, REPATHA, UBRELVY, VRAYLAR, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error